Mental Health
News Category
VERAXA Biotech Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
VERAXA Biotech highlights partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms, backed by new proof-of-concept data, at the upcoming BIO...
Quantum BioPharma’s Lucid-MS Targets Myelin Repair in Multiple Sclerosis, Poised for Phase 2 Trials
Quantum BioPharma is advancing Lucid-MS, a first-in-class neuroprotective therapy for multiple sclerosis that directly targets myelin repair, toward P...
Onco-Innovations Achieves Key Manufacturing Milestone for ONC010 Drug Candidate
Onco-Innovations completed a successful 300-gram scale-up batch of its ONC010 API with 99.3% purity, advancing its PNKP inhibitor program toward clini...
VERAXA Biotech Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
VERAXA Biotech AG is highlighting its BiTAC-ADC and BiTAC-TCE platforms, which show potential for improving cancer treatment precision and reducing of...
Quantum BioPharma’s Lucid-MS Targets Myelin Repair in Multiple Sclerosis, Advancing to Phase 2 Trials
Quantum BioPharma’s novel drug candidate Lucid-MS, which directly targets myelin repair, is preparing for phase 2 trials, offering a potential shift i...
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
The expansion of DNA Damage Response inhibitors beyond PARP inhibitors, led by companies like Onco-Innovations, AstraZeneca, and Boundless Bio, is dri...
Onco-Innovations Targets Next Wave of DNA Damage Response Cancer Therapies with PNKP Inhibitor
Onco-Innovations is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor, positioning itself as a potential leader in a novel class of cancer ...
NanoViricides Ships NV-387 Oral Gummies to DRC for Phase II MPox Trial
NanoViricides has shipped its broad-spectrum antiviral candidate NV-387 to the Democratic Republic of Congo for a Phase II clinical trial against MPox...
Soligenix Nears Key Clinical Milestones as Zacks Report Highlights HyBryte and Dusquetide Prospects
Soligenix is approaching critical clinical readouts in 2026, including the Phase 3 FLASH2 trial for HyBryte in CTCL and progress with dusquetide for B...
Okogen Acquires Ranpirnase Assets, Expanding Antiviral Pipeline Beyond Ophthalmology
Okogen Inc. has acquired the global intellectual property and development assets for ranpirnase from Orgenesis Inc., strengthening its ophthalmic prog...
Oragenics Reports Going Concern Audit Opinion, Raising Questions About Financial Stability
Oragenics Inc. disclosed a going concern audit opinion for fiscal 2025, highlighting potential financial risks as it advances its lead concussion trea...
Nutriband Selects Global Brand Name for AVERSA Fentanyl Patch, Targeting Abuse Deterrence
Nutriband announced the selection of a proposed worldwide brand name for its abuse-deterrent fentanyl patch, aiming to be the first such product to re...
Annovis Bio Highlights Buntanetap Development in The Scientist Publication
Annovis Bio's lead drug candidate buntanetap, featured in The Scientist, shows promise in Phase 3 trials for Alzheimer's and Parkinson's diseases.
Tonix Pharmaceuticals Reports Positive Phase 1 Data for Lyme Disease Prophylaxis Candidate TNX-4800
Tonix Pharmaceuticals announced Phase 1 results for TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention, showing sustained protect...
Lexaria Launches New Human Clinical Study Evaluating DehydraTECH-Semaglutide Tablets and Capsules Against Wegovy®
Lexaria Bioscience has initiated a 5-week human pilot study comparing two oral DehydraTECH-semaglutide formulations to commercial Wegovy® tablets, aim...
NanoViricides to Initiate Phase II MPox Trial in DRC, Advancing NV-387 Against Clade I Virus
NanoViricides announced plans to start a Phase II clinical trial of its antiviral NV-387 for MPox in the Democratic Republic of Congo, aiming to addre...
First Therapy Funded by California Taxpayer Dollars Approved for Rare Childhood Disorder
The FDA has approved KRESLADI, the first therapy funded by California's CIRM, for severe leukocyte adhesion deficiency-I, marking a milestone in regen...
OMRON Healthcare and UCSF Launch Randomized Controlled Trial for Early AFib Detection via Home Blood Pressure Monitoring
OMRON Healthcare and UCSF have initiated a randomized controlled trial to evaluate whether home blood pressure monitors with AFib detection can improv...
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) 4Q25; Highlights Regulatory Progress and Financial Runway
Cingulate's ADHD drug CTx-1301 NDA remains under FDA review with only manufacturing issues remaining, supported by recent financing and a ~$23M cash r...
NanoViricides Files for Rare Pediatric Disease Designation for Measles Drug Candidate NV-387
NanoViricides has filed for Rare Pediatric Disease Drug designation for NV-387 as a measles treatment, potentially qualifying for a Priority Review Vo...
BioStem Technologies to Present Expanded Product Portfolio and Clinical Data at SAWC Spring 2026
BioStem Technologies will showcase its new Neox product line and clinical evidence at the Symposium on Advanced Wound Care, highlighting its commitmen...
Aclarion Partners with Weill Cornell Medicine to Expand Nociscan Use in Chronic Low Back Pain Trial
Aclarion's Nociscan technology will be used in a Weill Cornell Medicine trial investigating stem cell therapy for discogenic low back pain, potentiall...
HITN to Broadcast 'The Long Road to Hope' Documentary for World Parkinson's Day
HITN will air a documentary on Parkinson's disease, highlighting the estimated 200,000 Hispanics in the U.S. living with the condition and emphasizing...
Oragenics Doses First Patient in Phase IIa Trial of Concussion Treatment ONP-002
Oragenics has dosed the first patient in its Phase IIa trial of ONP-002 for concussion, targeting a large unmet need with no FDA-approved pharmacologi...
NeuroOne Partners with University of Minnesota to Advance Localized Drug Delivery for Epilepsy
NeuroOne Medical Technologies has entered a collaboration with the University of Minnesota to evaluate next-generation epilepsy therapies using its sE...
Tonix Pharmaceuticals Announces Publication of TONMYA Pharmacokinetic Study in Peer-Reviewed Journal
A study published in Clinical Pharmacology in Drug Development demonstrates that Tonix's sublingual TONMYA achieves faster absorption and higher bioav...
Oragenics Reports Early Dosing Progress in Phase IIa Trial of Intranasal Concussion Therapy
Oragenics has enrolled two patients and administered eight doses in its Phase IIa trial for ONP-002, a first-in-class intranasal neurosteroid for mild...
NanoViricides Highlights NV-387 as Potential Measles Treatment Amid Global Outbreak Surge
NanoViricides announced that its antiviral drug candidate NV-387 could address the growing global measles outbreak, having shown safety in Phase I tri...
First PEO for Digital Creators Launches, Offering Fortune 500 Health Benefits
EssentL Creators launches as the first PEO built exclusively for YouTubers and digital creators, providing access to group health benefits and HR comp...
AI Tool Ask Eolas Achieves 100% Prescribing Accuracy in Landmark Study
A peer-reviewed study published in npj Antimicrobials and Resistance shows that Ask Eolas, an AI-powered clinical decision support system, eliminated ...
Newron Shareholders Approve Board Changes at AGM 2026
Newron Pharmaceuticals' AGM 2026 approved the election of two new independent board members, while extraordinary resolutions were postponed due to lac...
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Enhancing Precision in Cancer Therapy
VERAXA Biotech announced new in vitro data showing its BiTAC-ADC platform distinguishes cancer from healthy cells, minimizing toxicity and supporting ...
Creative Biolabs Launches End-to-End ASO Development Services to Accelerate RNA Therapeutics
Creative Biolabs announces integrated antisense oligonucleotide (ASO) development services that combine bioinformatics, chemical synthesis, and precli...
Tonix Pharmaceuticals Reports Phase 1 Data and Plans Phase 2 Study for Lyme Disease Prevention Candidate
Tonix Pharmaceuticals announced Phase 1 data and plans for a Phase 2 field study of TNX-4800, a long-acting monoclonal antibody for Lyme disease preve...
International Healthcare Week to Showcase Hong Kong as Medtech and Investment Hub
The fifth International Healthcare Week, featuring the Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair, will ...
Aclarion Reports 196% Scan Volume Growth in Q1 2026, Signaling Accelerating Clinical Adoption of Nociscan
Aclarion's first quarter 2026 results show a 196% year-over-year increase in Nociscan scan volumes, driven by growing physician adoption and reimburse...
BioVersys Shareholders Approve All Board Proposals at Annual General Meeting
BioVersys AG announced that shareholders approved all board proposals at the AGM, including re-election of directors and compensation packages, unders...
NanoViricides Receives Orphan Drug Designation for NV-387 to Treat Measles Amid Global Outbreaks
NanoViricides' NV-387 obtains FDA Orphan Drug Designation for measles, offering incentives and supporting development against rising global outbreaks.
Aclarion Expands Nociscan Use in Second Weill Cornell Trial Led by Dr. Roger Härtl
Aclarion's second commercial agreement with Weill Cornell Medicine introduces Nociscan into a prospective randomized trial led by Dr. Roger Härtl, aim...
Oragenics Advances Phase IIa Trial Enrollment for Concussion Treatment Candidate ONP-002
Oragenics has initiated enrollment at a second site for its Phase IIa trial of ONP-002 for concussion, with four patients dosed in Australia, aiming f...
Tonix Pharmaceuticals Secures GPO Agreement Covering 35 Million Lives for TONMYA, Expanding Access to Non-Opioid Fibromyalgia Treatment
Tonix Pharmaceuticals announced a GPO agreement covering approximately 35 million U.S. commercial lives for its FDA-approved fibromyalgia treatment TO...
NanoViricides to Present at D. Boral Capital Global Conference, Highlighting Progress of Broad-Spectrum Antiviral NV-387
NanoViricides announces its participation in the D. Boral Capital Global Conference, where it will discuss its lead antiviral drug NV-387, which has c...
Annovis Bio CEO to Present Multi-Protein Alzheimer’s Research at Fierce Biotech Week 2026
Annovis Bio CEO Maria Maccecchini will present at Fierce Biotech Week 2026 on treating Alzheimer’s as a multi-protein disorder, highlighting buntaneta...
Oragenics Signs LOI to License CardioDialysis Technology for Neurological Applications
Oragenics Inc. has signed a letter of intent to license Sigyn Therapeutics' CardioDialysis blood purification technology for traumatic brain injury an...
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform, Demonstrating Tumor-Selective Killing
VERAXA Biotech announced new in vitro data validating its BiTAC-ADC platform, which shows selective killing of breast cancer cells while sparing healt...
Oncotelic Therapeutics Launches AI-Powered GMP Manufacturing Platform at BIO 2026
Oncotelic Therapeutics announced its AI-driven GMP manufacturing platform, integrating PDAOAI and robotics, to modernize pharmaceutical production, wi...
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Innovations in central nervous system drug delivery, particularly nose-to-brain platforms, are addressing the blood-brain barrier bottleneck and openi...
NanoViricides Highlights Broad-Spectrum Antiviral Candidate Following Andes Hantavirus Incident
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential therapeutic platform for emerging viral threats after the Andes h...